Short answer
Verastem, Inc. (VSTM) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $11M with net income of −$99M.
Q3 2025 key financials · XBRL
- Revenue
- $11M
- +426.1% QoQ
- Net income
- −$99M
- −311.1% YoY · −279.9% QoQ
- Operating margin
- -362.2%
- EPS (diluted)
- −$1.32
- −144.4% YoY · −193.3% QoQ
Source: XBRL data from the Verastem, Inc. (VSTM) Q3 2025 10-Q on SEC EDGAR. USD.
Verastem, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New regulatory risk: September 2025 FDA enforcement surge, with more than 100 warning or untitled letters on allegedly deceptive DTC advertising
- Drug-pricing reform exposure: April and May 2025 Executive Orders targeting Medicare negotiation, importation, generics, and most-favored-nation pricing
- Marketing compliance risk: Planned FDA rulemaking could require additional safety disclosures in DTC broadcast advertisements
- Policy uncertainty: January 2025 presidential transition may raise approval standards or restrict AVMAPKI FAKZYNJA CO-PACK promotion
- Commercial risk: Expanded FDA oversight of digital and social-media advertising could constrain Verastem’s sales efforts
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Verastem, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.